| Drug targeting and repositioning |
|
Gencron is a service offering covering the optimum match of genetically identified patient groups to oncology drugs, which are currently under clinical and pre-clinical development (so called drug targeting) but also drugs which failed to achieve the expected milestones during their development cycle (drug repositioning). The service is based on the fundamental priciples of modern pharmacogenomics. The drugs which have been tested on genetically identified patient groups allow the doctors to select the most appropriate therapy depending on the individual patient’s genome. This in turn leads to better treatment results, fewer side effects and reduced risk of applying drugs which are completely inefficient for the particular patient. The application of genetically-profiled drugs is one of the elements of personalized medicine. Gencron team utilizes the recent discoveries identifying the influence of single nucleotide polymorphisms (SNPs) in patient genomes on the origins and development of neoplasm and related drug interactions. The discoveries have already resulted in many patents and patent applications in USA and Europe. Gencron is the result of a strategic research, development and marketing partnership in the area of genetic background of neoplasm development and related treatments between Read-Gene headquartered in Szczecin, Poland and Selvita, headquartered in Krakow, Poland. The goal of the cooperation is to take advantage of the best of scientific, technical and business competencies of both companies in order to develop novel oncology diagnostics and treatment solutions. The foundation of the partnership is laid on twenty years of research of Read-Gene team into the genetic background of neoplasm development and its latest research on genomic-based targeting of cancer therapies.  Read more: Gencron About Read-GeneRead-Gene is a biomedical research company founded in 2005. The mission of the company is commercial application of the methods of identification, prevention and treatment of most frequent malignant tumors. Most discoveries have been made at International Hereditary Cancer Center of the Pomeranian Medical University, founded in 1992 and based in Szczecin, Poland. IHCC research targeted at prevention, diagnostics and treatment of tumors has been published in many leading research journals. The main achievements of IHCC are:
More about Read-Gene: http://www.read-gene.com. |